People who are suffering from clinical depression may have some better drugs in the market now. The Food and Drug Administration of the United States has given approval to a depression drug named esketamine — which is derived from ketamine. This medicine has been designed for patients who haven’t had noticeable improvements from the use of standard anti-depressants present in the market. It needs to be noted that, unlike the traditional anti-depressants, esketamine would be a fast-acting drug for those who are suffering from depression.
While an anti-depressant takes up to a few weeks to lift the mood of the patient, esketamine can do the same within hours. That having said, FDA recommends the drug only to those who have tried normal anti-depressants and did not have enough improvement. “Because of the risk of serious adverse outcomes resulting from sedation and dissociation caused by Spravato administration, and the potential for abuse and misuse of the drug, it is only available through a restricted distribution system, under a Risk Evaluation and Mitigation Strategy (REMS),” added FDA as it was talking about the restrictions of availability of the newly approved drug for depression.
“Patients with a major depressive disorder who, despite trying at least two antidepressant treatments given at adequate doses for an adequate duration in the current episode, have not responded to treatment are considered to have treatment-resistant depression,” added the agency in its press release. Of course, one of the reasons behind the huge excitement is the fact that ketamine has been found to be effective earlier. Ketamine is found to have a quick impact on individuals suffering from depression. Following these findings, a number of clinics are offering ketamine treatment across the US. Now that an official drug is available from the same source, it would be easier for patients.